JP2021529796A5 - - Google Patents
Info
- Publication number
- JP2021529796A5 JP2021529796A5 JP2021500040A JP2021500040A JP2021529796A5 JP 2021529796 A5 JP2021529796 A5 JP 2021529796A5 JP 2021500040 A JP2021500040 A JP 2021500040A JP 2021500040 A JP2021500040 A JP 2021500040A JP 2021529796 A5 JP2021529796 A5 JP 2021529796A5
- Authority
- JP
- Japan
- Prior art keywords
- fzd
- binding region
- wnt
- lrp5
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023186681A JP2024001292A (ja) | 2018-07-05 | 2023-10-31 | 多特異性Ｗｎｔ代替分子及びその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694339P | 2018-07-05 | 2018-07-05 | |
| US62/694,339 | 2018-07-05 | ||
| US201862782122P | 2018-12-19 | 2018-12-19 | |
| US62/782,122 | 2018-12-19 | ||
| US201962797772P | 2019-01-28 | 2019-01-28 | |
| US62/797,772 | 2019-01-28 | ||
| PCT/US2019/040687 WO2020010308A1 (en) | 2018-07-05 | 2019-07-05 | Multi-specific wnt surrogate molecules and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186681A Division JP2024001292A (ja) | 2018-07-05 | 2023-10-31 | 多特異性Ｗｎｔ代替分子及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021529796A JP2021529796A (ja) | 2021-11-04 |
| JP2021529796A5 true JP2021529796A5 (enExample) | 2022-07-12 |
Family
ID=69059929
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500040A Pending JP2021529796A (ja) | 2018-07-05 | 2019-07-05 | 多特異性Ｗｎｔ代替分子及びその使用 |
| JP2023186681A Withdrawn JP2024001292A (ja) | 2018-07-05 | 2023-10-31 | 多特異性Ｗｎｔ代替分子及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186681A Withdrawn JP2024001292A (ja) | 2018-07-05 | 2023-10-31 | 多特異性Ｗｎｔ代替分子及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210292422A1 (enExample) |
| EP (2) | EP3820906B1 (enExample) |
| JP (2) | JP2021529796A (enExample) |
| CN (2) | CN120623353A (enExample) |
| AU (2) | AU2019297522B2 (enExample) |
| CA (1) | CA3104526A1 (enExample) |
| DK (1) | DK3820906T3 (enExample) |
| ES (1) | ES3058239T3 (enExample) |
| PL (1) | PL3820906T3 (enExample) |
| WO (1) | WO2020010308A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018211985B2 (en) | 2017-01-26 | 2025-02-13 | Surrozen Operating, Inc. | Tissue-specific Wnt signal enhancing molecules and uses thereof |
| CN111699003B (zh) | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
| JP7418332B2 (ja) * | 2017-12-19 | 2024-01-19 | スロゼン オペレーティング， インコーポレイテッド | 抗フリズルド抗体及び使用方法 |
| CN118271444A (zh) * | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| US20210032352A1 (en) * | 2018-02-14 | 2021-02-04 | Antera Therapeutics Inc. | Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof |
| JP2021530223A (ja) | 2018-07-09 | 2021-11-11 | スロゼン， インコーポレイテッド | 組織特異性Ｗｎｔシグナル増強分子及びその使用 |
| CA3144499A1 (en) * | 2019-07-02 | 2021-01-07 | Surrozen Operating, Inc. | Monospecific anti-frizzled antibodies and methods of use |
| US20230138045A1 (en) * | 2020-02-24 | 2023-05-04 | Surrozen Operating, Inc. | Wnt super agonists |
| WO2022104280A1 (en) | 2020-11-16 | 2022-05-19 | Surrozen Operating, Inc. | Liver-specific wnt signal enhancing molecules and uses thereof |
| CA3204321A1 (en) | 2020-12-18 | 2022-06-23 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
| WO2023250402A2 (en) * | 2022-06-22 | 2023-12-28 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
| CR20240266A (es) * | 2021-12-31 | 2024-11-11 | Surrozen Operating Inc | Compuesto específico de receptor wnt y método relacionado con este |
| AU2024279826A1 (en) * | 2023-05-29 | 2026-01-08 | Surrozen Operating, Inc. | Wnt surrogate agents and methods for lacrimal gland regeneration |
| WO2026044275A1 (en) * | 2024-08-23 | 2026-02-26 | Surrozen Operating, Inc. | Wnt surrogate fusion molecule |
| WO2026044274A1 (en) * | 2024-08-23 | 2026-02-26 | Surrozen Operating, Inc. | Wnt surrogate fusion molecule |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US20030044409A1 (en) | 2001-05-01 | 2003-03-06 | Carson Dennis A. | Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| BRPI0514068B8 (pt) | 2004-08-04 | 2021-05-25 | Applied Molecular Evolution Inc | anticorpo anti-cd20, e, composição farmacêutica |
| DE102004050620A1 (de) | 2004-10-13 | 2006-04-20 | Eberhard-Karls-Universität Tübingen | Monoklonaler Antikörper gegen Frizzled-Rezeptoren |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| JP2008528010A (ja) | 2005-01-31 | 2008-07-31 | アブリンクス ナームローゼ フェンノートシャップ | 重鎖抗体の可変ドメイン配列を作出する方法 |
| AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
| DE102005035568A1 (de) | 2005-07-25 | 2007-02-01 | M-Phasys Gmbh | Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| US8221751B2 (en) | 2006-06-21 | 2012-07-17 | Oncotherapy Science, Inc. | Tumor-targeting monoclonal antibodies to FZD10 and uses thereof |
| MX2010004761A (es) * | 2007-11-02 | 2010-05-19 | Novartis Ag | Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6). |
| EP3211011A1 (en) | 2007-11-16 | 2017-08-30 | Nuvelo, Inc. | Antibodies to lrp6 |
| EP2331136B1 (en) | 2008-09-26 | 2018-01-10 | OncoMed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| US8642339B2 (en) | 2009-02-03 | 2014-02-04 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising the stem cells |
| KR101899835B1 (ko) | 2010-03-24 | 2018-09-19 | 제넨테크, 인크. | 항-ｌｒｐ６ 항체 |
| CN102971337B (zh) | 2010-04-01 | 2016-09-21 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
| AU2014306564B2 (en) | 2013-08-14 | 2019-10-17 | Antlera Therapeutics Inc. | Antibodies against frizzled proteins and methods of use thereof |
| GB2519786A (en) * | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| JP6796059B2 (ja) * | 2014-09-12 | 2020-12-02 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｗｎｔシグナリングアゴニスト分子 |
| WO2016205566A1 (en) | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| WO2016205551A2 (en) | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| PT3383425T (pt) * | 2015-12-04 | 2020-10-07 | Boehringer Ingelheim Int | Polipéptidos biparatópicos que antagonizam a sinalização wnt em células tumorais |
| WO2017127933A1 (en) | 2016-01-29 | 2017-08-03 | The Governing Council Of The University Of Toronto | Frizzled protein-binding agents and methods of use thereof |
| JP7014724B2 (ja) | 2016-02-06 | 2022-02-01 | エピムアブ バイオセラピューティクス インコーポレイテッド | タンデム型Ｆａｂ免疫グロブリンおよびその使用 |
| CN118271444A (zh) | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| US20210032352A1 (en) * | 2018-02-14 | 2021-02-04 | Antera Therapeutics Inc. | Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof |
-
2019
- 2019-07-05 AU AU2019297522A patent/AU2019297522B2/en active Active
- 2019-07-05 PL PL19830971.8T patent/PL3820906T3/pl unknown
- 2019-07-05 CN CN202510662154.5A patent/CN120623353A/zh active Pending
- 2019-07-05 DK DK19830971.8T patent/DK3820906T3/da active
- 2019-07-05 EP EP19830971.8A patent/EP3820906B1/en active Active
- 2019-07-05 ES ES19830971T patent/ES3058239T3/es active Active
- 2019-07-05 JP JP2021500040A patent/JP2021529796A/ja active Pending
- 2019-07-05 EP EP25208409.0A patent/EP4733325A3/en active Pending
- 2019-07-05 CN CN201980052601.8A patent/CN112566940B/zh active Active
- 2019-07-05 CA CA3104526A patent/CA3104526A1/en active Pending
- 2019-07-05 WO PCT/US2019/040687 patent/WO2020010308A1/en not_active Ceased
- 2019-07-05 US US17/257,817 patent/US20210292422A1/en active Pending
-
2023
- 2023-10-31 JP JP2023186681A patent/JP2024001292A/ja not_active Withdrawn
-
2026
- 2026-07-20 AU AU2026206257A patent/AU2026206257A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021508247A5 (enExample) | ||
| JP2021508683A5 (enExample) | ||
| CN112566940B (zh) | 多特异性wnt替代分子和其用途 | |
| CN111655729B (zh) | 抗卷曲蛋白抗体和使用方法 | |
| JP7317016B2 (ja) | 抗ｌｒｐ５／６抗体及び使用方法 | |
| JP2023113950A (ja) | Ｗｎｔサロゲート分子及びその使用 | |
| JP6647208B2 (ja) | 抗ｉｌ−１７抗体、その生産および使用のための方法 | |
| JP2026016376A5 (enExample) | ||
| JP2022553830A (ja) | Ｎ末端ｓｃＦｖ多重特異性結合分子 | |
| CN103649118A (zh) | 双特异性结合剂 | |
| JP2018504907A (ja) | ＦｃＲｎ抗体およびその使用方法 | |
| JP2018502050A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| TW201631153A (zh) | 具有替代血液凝固第ｖｉｉｉ因子之功能的多重專一性抗原結合分子 | |
| RU2009133789A (ru) | Способы лечения глазных болезней | |
| CA2935285A1 (en) | Anti-pcsk9-glp-1 fusions and methods for use | |
| CA3204321A1 (en) | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof | |
| WO2009040336A1 (en) | Antigen binding proteins | |
| WO2019195313A1 (en) | Anti-vegf antagonist and pedf agonist constructs and uses thereof | |
| JP2020524658A5 (enExample) | ||
| JP2023549854A5 (enExample) | ||
| JP2025134864A5 (enExample) | ||
| JP2022539212A (ja) | 単一特異性抗Ｆｒｉｚｚｌｅｄ抗体および使用の方法 | |
| CN107074963A (zh) | 抑制血管内皮脂肪酶的酶活性的人源化单克隆抗体 | |
| CA2981115A1 (en) | Anti-dkk-1-anti-rankl bispecific antibody compounds |